Sapienza University, 2nd School of Medicine, Advanced Molecular Diagnostic Unit, Department of Biochemical Sciences, Rome, Italy.
Expert Opin Drug Metab Toxicol. 2011 Jan;7(1):39-47. doi: 10.1517/17425255.2011.538680. Epub 2010 Dec 11.
Migraine is a debilitating and painful neurological disorder affecting millions of people worldwide and often worsened by chronification. Triptans represent a powerful pharmacological resource in migraine management; nevertheless, a significant portion of treated patients do not obtain consistent pain relief through triptans. Pharmacogenomics may offer a new way to rationalise triptans administration, based on characterisation of the individual genomic profile.
The review summarises the results of association studies between polymorphisms in genes involved in the kinetics and dynamics of triptans, and clinical response to them in migraineurs.
A summary of data available at present from genetic studies in the field of triptan therapy in migraine, and a picture of the difficulties facing research into the pharmacogenomics of triptans.
Pharmacogenomic studies of triptans suggest that some genetic determinants influence drug response, but the complexity of the field calls for application of a systematic approach to genetic association studies, allowing identification of a therapy response prediction panel with adequate predictive power.
偏头痛是一种使人虚弱和痛苦的神经障碍，影响着全世界数以百万计的人，而且常常因慢性化而恶化。曲坦类药物是偏头痛治疗中强有力的药理学资源；然而，相当一部分接受治疗的患者并没有通过曲坦类药物获得一致的疼痛缓解。基于个体基因组特征的描述，药物基因组学可能为合理管理曲坦类药物提供一种新方法。
这篇综述总结了与曲坦类药物动力学和动态学相关基因的多态性，以及偏头痛患者对它们的临床反应之间的关联研究结果。
目前在偏头痛曲坦治疗领域遗传研究中可用数据的摘要，以及曲坦药物基因组学研究面临的困难的概述。
曲坦类药物的药物基因组学研究表明，一些遗传决定因素会影响药物反应，但该领域的复杂性要求对遗传关联研究应用系统方法，从而确定具有足够预测能力的治疗反应预测面板。
